Vor bio reports fourth quarter and full year 2024 financial results and provides company update

Vcar33 clinical data update planned for first half of 2025 and trem-cel + mylotarg clinical data update planned for second half of 2025 anticipate initiation of the first trem-cel+vcar33 treatment system clinical trial in second half of 2025 $55.6 million private placement completed in december 2024 cambridge, mass., march 20, 2025 (globe newswire) -- vor bio (nasdaq: vor), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period and full year ended december 31, 2024, and provided a business update.
VOR Ratings Summary
VOR Quant Ranking